NCT01772797View on ClinicalTrials.gov

Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Anaplastic Lymphoma Kinase (ALK)Non-small Cell Lung Cancer
Interventions
DRUG

LDK378

LDK378 is a capsule to be taken daily by mouth.

DRUG

AUY922

AUY922 is an intravenous infusion that will be administered by the investigative site to the patient on a weekly basis.

Trial Locations (8)

3000

Novartis Investigative Site, Melbourne

20141

Novartis Investigative Site, Milan

80045

University of Colorado Dept. of Anschutz Cancer (3), Aurora

84103

University of Utah / Huntsman Cancer Institute Huntsman, Salt Lake City

169610

Novartis Investigative Site, Singapore

02114

Massachusetts General Hospital Mass General, Boston

19111-2497

Fox Chase Cancer Center Fox Chase Cancer (2), Philadelphia

08035

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY